This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ward, R. M.
Right arrow Articles by Molteni, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, R. M.
Right arrow Articles by Molteni, R. A.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 103 No. 2 February 1999, pp. 469-472

Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns

Received Aug 18, 1998; accepted Nov 4, 1998.

Robert M. Ward*, James A. LemonsDagger , and Richard A. Molteni§

From the * Department of Pediatrics, University of Utah, Salt Lake City, Utah; Dagger  Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana; and § Department of Pediatrics, Thomas Jefferson School of Medicine, Philadelphia, Pennsylvania.

Objective.  This survey estimated the frequency of use and adverse events associated with cisapride treatment of premature newborns in intensive care units. It was initiated in response to a warning issued in Canada cautioning against cisapride treatment of premature infants of <36 weeks' gestation and <3 months of age.

Methodology.  Surveys were mailed to 105 neonatology training program directors to obtain the total number of neonatal intensive care unit (NICU) admissions, the number of admissions of infants of <36 weeks' gestation, the number of years that cisapride had been used, the estimated percent/number of premature patients treated with cisapride per year, and the frequency and nature of arrhythmias or other adverse events associated with cisapride treatment. Of 105 programs, 46 responded to a single mailing of the first survey. A second survey mailed to the 45 respondents to the first survey sought to determine the indications, diagnostic tests, and dosages used with cisapride treatment of premature newborns. Of the 45 programs, 26 responded to the second survey.

Results.  More than 58 000 premature newborns of <36 weeks' gestation were admitted to the NICUs we surveyed, and ~19% were treated with cisapride. No deaths attributable to cisapride were reported among >11 000 preterm newborns treated. Three nonfatal arrhythmias were reported; two associated with 10-fold dosing errors and one with co-treatment with erythromycin, a macrolide antibiotic that reduces the metabolism of cisapride. Diarrhea was reported in 12 patients, and reversible liver enzyme changes were noted in one patient. Typically, cisapride treatment was started in dosages of 0.1 to 0.2 mg/kg/dose, repeated every 6 to 8 hours. Treatment usually was begun empirically, without a preceding study to document gastroesophageal reflux. The most frequent indications for cisapride treatment were choking or gagging, with associated apnea, bradycardia, and desaturation. Approximately 50% of patients had discontinued cisapride treatment before discharge. Eighty-four percent of clinicians judged cisapride to be effective for the problems being treated.

Conclusions.  Cisapride treatment of premature infants of <36 weeks' gestation and <3 months of age in NICUs appears to be widespread in the United States. Complications and adverse events were seen when cisapride was administered in excessive dosages or in combination with a drug that inhibits its metabolism and leads to increased serum concentrations. Severe toxicities such as arrhythmias were reported with a frequency of <1/11 000 NICU admissions. However, in a retrospective survey, episodes of toxicity, including mortality, attributable to cisapride may not have been recognized or reported.  Key words:  cisapride, arrhythmias, drug toxicity, neonates, gastroesophageal reflux, overdose, survey, neonatology training programs.




This article has been cited by other articles:


Home page
 EDUCATION AND PRACTICEHome page
S. Keady
Update on drugs for gastro-oesophageal reflux disease
Arch. Dis. Child. Ed. Pract., August 1, 2007; 92(4): ep114 - ep118.
[Full Text] [PDF]

Home page
 PediatricsHome page
C. F. Poets
Gastroesophageal Reflux: A Critical Review of Its Role in Preterm Infants
Pediatrics, February 1, 2004; 113(2): e128 - 132.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Dubin, M. Kikkert, M. Mirmiran, and R. Ariagno
Cisapride Associated With QTc Prolongation in Very Low Birth Weight Preterm Infants
Pediatrics, June 1, 2001; 107(6): 1313 - 1316.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
D S Semama, S Bernardini, S Louf, B Laurent-Atthalin, and J-B Gouyon
Effects of cisapride on QTc interval in term neonates
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2001; 84(1): 44F - 46.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
M MARKIEWICZ and Y VANDEN PLAS
Should cisapride have been "blacklisted"?
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2000; 82(1): 3F - 4.
[Full Text]

Home page
 Arch. Dis. Child.Home page
S. W JONES and M. WAGSTAFF
Risks and benefits of cisapride
Arch. Dis. Child., June 1, 1999; 80(6): 579i - 579.
[Full Text]